| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Bergman, M, et al.
(författare)
-
Intendedness of pregnancies and preconception contraceptive use in women of Swedish and non-European origins seeking emergency care in early pregnancy
- 2022
-
Ingår i: BMJ sexual & reproductive health. - : BMJ. - 2515-2009 .- 2515-1991. ; 48:1, s. 41-46
-
Tidskriftsartikel (refereegranskat)abstract
- Unintended pregnancies in Europe have been estimated to constitute 43% of all pregnancies, with the proportion in Sweden being unknown. In striving for equitable healthcare, increased knowledge about unintended pregnancies among women born outside Europe is needed. We aimed to estimate the proportion of unintended pregnancies in women born in Sweden compared with women born outside Europe in an unselected population seeking gynaecological emergency care in early pregnancy. Our secondary aim was to compare contraceptive use at the time of conception in unplanned pregnancies between women born in Sweden and women born outside Europe.MethodsPregnant women seeking gynaecological emergency care in early pregnancy at a tertiary hospital were asked to fill out a questionnaire in their native language. The questionnaire contained questions from the London Measure of Unplanned Pregnancy (LMUP) and questions regarding sociodemographic data, gynaecological health and previous contraception.ResultsOf 180 pregnancies, 66 were unintended (36.7%) according to the LMUP. Among patients born in Sweden, 49/129 (38.0%) of the pregnancies were unintended compared with 17/51 (33.3%) among patients born outside Europe (p=0.56). 86% of participants with unintended pregnancy did not use any form of contraception during the month of conception, with no difference between women born in Sweden and those born outside Europe.ConclusionsAmong women seeking gynaecological emergency care in early pregnancy, unintended pregnancies are common. Women with unintended pregnancies had low use of preconception contraceptives, which highlights a need for further interventions aimed at avoiding unintended pregnancies.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
- Kallner, HK, et al.
(författare)
-
June 24th, 2022: once a right is obtained, it can no longer be lost!
- 2022
-
Ingår i: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. - : Informa UK Limited. - 1473-0782. ; 27:4, s. 271-271
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
| 26. |
- Kwak, YK, et al.
(författare)
-
Persistence of Lactobacilli in Postmenopausal Women - A Double-Blind, Randomized, Pilot Study
- 2017
-
Ingår i: Gynecologic and obstetric investigation. - : S. Karger AG. - 1423-002X .- 0378-7346. ; 82:2, s. 144-150
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Aim:</i></b> To investigate the ability of lactobacilli to persist in the genital area (vagina and labia) of women after the topical application of an ointment containing <i>Lactobacillus gasseri</i> LN40, <i>L. fermentum</i> LN99 and <i>L. rhamnosus</i> LN113. Secondary objectives were to study the presence of <i>Escherichia coli</i> and other contaminants, as well as subjective symptoms in the genital tract. <b><i>Methods:</i></b> Eighteen healthy postmenopausal women were randomized to use either the study product or placebo for 10 days. Gynecological examinations, labial and vaginal samplings for bacterial cultivation were performed at baseline (visit 1), after treatment (visit 2), and at a 10-day follow-up (visit 3). LN strains were identified by specific cultivation methods. Subjective symptoms were evaluated by a self-administered questionnaire. <b><i>Results:</i></b> The presence of LN99 was shown in 7 out of 8 women in the investigational group at visit 2 (p < 0.001 compared to placebo) and in 5 out of 8 at visit 3 (p < 0.05), whereas the presence of LN113 was shown in 2 out of 8 at visit 2 and in 1 out of 8 at visit 3. Subjective symptoms were significantly reduced (p < 0.01) at visits 2 and 3 for both products. <b><i>Conclusion:</i></b> Topical application of a probiotic ointment is feasible to achieve persistence of lactobacilli for at least 10 days.
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
|
|
| 33. |
|
|
| 34. |
|
|
| 35. |
|
|
| 36. |
|
|
| 37. |
|
|
| 38. |
|
|
| 39. |
|
|
| 40. |
|
|
